Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Luveltamab tazevibulin
SUTRO BIOPHARMA, INC.
Ovarian Cancer
1 trial -
Lynparza 100 mg film-coated tablets, ABIRATERONE , PREDNISOLONE , Lynparza 150 mg film-coated tablets
AstraZeneca AB
Metastatic castration-resistant prostate cancer
1 trial -
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
The George Institute
Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
1 trial -
Lynparza 100 mg film-coated tablets, Placebo - film-coated tablets, Lynparza 150 mg film-coated tablets
AstraZeneca AB
Breast Cancer
1 trial -
Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7
The George Institute
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
1 trial -
Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets
AstraZeneca AB
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer
1 trial -
Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB
Fondazione Telethon ETS
Recurrent ovarian cancer
1 trial -
MAT2203
Matinas BioPharma Holdings
Cryptococcal Meningitis
2 trials -
MB-102 DMID
Hangzhou Zhongmei Huadong Pharmaceutical Co.,
Kidney Diseases
1 trial -
MC0518, EVEROLIMUS, MYCOPHENOLIC ACID , ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Steroid refractory Acute Graft versus host Disease
1 trial -
MCV-ACYW135 Vaccine Group
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningitis
1 trial -
MEDI4736
AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
1 trial -
MEDI4736
AstraZeneca
Non-Small Cell Lung Cancer
1 trial -
MEDI4736 (Durvalumab)
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
1 trial -
MEDI4736 Placebo, DURVALUMAB
CERO THERAPEUTICS HOLDINGS, INC.
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
1 trial -
MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE
Merck Sharp and Dohme
Breast cancer, Ovarian cancer, Endometrial cancer
1 trial -
MELATONINE ARROW LP 2 mg, comprimé à libération prolongée, PLACEBO DE MELATONINE ARROW LP 2 mg comprimé
Pari Pharma GmbH
insomnia, Depressive episode
1 trial -
MEP
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
MEPOLIZUMAB
GlaxoSmithKline
Hypereosinophilic syndrome (HES)
1 trial -
MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph
Iovance Biotherapeutics B.V.
Melanoma
1 trial -
METFORMIN
Pari Pharma GmbH
Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug
1 trial -
METFORMIN , DAPAGLIFLOZIN
Eli Lilly Co.
Type 2 Diabetes
1 trial -
METFORMIN, COLCHICINE
Disc Medicine
PASC: post-acute sequelae of SARS-CoV-2 infection
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources